Pfizer Inc said it reached a $2.15 billion settlement with Teva Pharmaceuticals Industries Ltd and Sun Pharmaceutical Industries Ltd related to patent infringement on its acid-reflux drug Protonix.
Japan's Takeda Pharmaceutical Co Ltd, Pfizer's partner, will receive 36 percent or about $774 million from the settlement.
Pfizer won a protracted 10-year legal battle in April 2010 when a New Jersey jury ruled that Teva had infringed the Protonix patent. Teva started selling a generic version of the drug in 2007. A trial to determine damages began on Monday.
The patent was held by Nycomed- now a Takeda subsidiary. Protonix was licensed to Wyeth, which is now owned by Pfizer.
Israel-based Teva will pay $800 million in 2013 and the remaining $800 million by October 2014. India's Sun Pharma will make its entire payment of $550 million in 2013.
Teva said in February that it may face legal losses of up to $2.07 billion to resolve the case.
Sun Pharma set aside 5.84 billion rupees, or about $100 million, last November towards potential damages to Pfizer. The company will now have to shell out a further $450 million as final settlement.
"This is not a very positive out-of-court settlement. The agreed amount is way too high for such a settlement," said Daljeet Kohli, head of research at brokerage IndiaNivesh in Mumbai. "It will also restrict Sun's ability to look for acquisitions."
Pfizer's shares were up about 1 percent at $28.66 before the bell, while Teva's U.S.-listed shares were down about 1 percent at $39.51.
Sun Pharma closed little changed at 980.70 rupees, while Takeda's stock closed down 1.4 percent at 4,355 yen. For CNBC-TV18 comments watch video.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
